Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
December 13, 2023 22:09 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
December 13, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
November 08, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
November 07, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial...
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
November 01, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a...
Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
October 24, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
October 03, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative...
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
September 06, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 09, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
August 07, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.5 million Credit Facility; Cash Runway Now Forecasted...